NEW YORK, New York — September 15, 2025 — Leads & Copy — Conceivable Life Sciences has announced a $50 million Series A funding round to accelerate the development and commercialization of its AI-powered automated IVF laboratory, with the goal of improving accessibility, scalability, and effectiveness of IVF treatments.
The Series A round was led by Advance Venture Partners (AVP) with participation from existing investors including ARTIS Ventures, Stride, and ACME. The funding brings Conceivable’s total to $70 million, including a $20 million seed round that closed in December 2022.
Conceivable is revolutionizing IVF through its proprietary automated IVF lab platform: AURA. This brings robotic precision and AI algorithmic exactitude to remove variability and standardize the more than 200 intricate steps with the aim to deliver consistently successful IVF outcomes.
According to Alan Murray, co-founder and CEO of Conceivable, the funding validates the company’s vision of transforming IVF through AI-powered robotic automation. He noted that the platform addresses challenges facing fertility clinics such as unpredictable success rates, capacity constraints, and accessibility barriers.
Conceivable is in active clinical operations and currently conducting a 100-patient pilot study. Dr. Alejandro Chavez-Badiola, reproductive endocrinologist, co-founder, and Chief Medical Officer of Conceivable, noted that ongoing pregnancy results from the current trial are positive, with 18 healthy babies from an earlier study on prototype instruments.
The Series A funding will support Conceivable Life Sciences’s U.S. debut next year, expanding its partnerships with fertility networks in 2026—marking the U.S. commercial launch of the world’s first automated IVF lab.
The global fertility market faces challenges including rising demand, limited clinic capacity, and cost barriers that affect accessibility. Conceivable tackles key challenges in the lab by boosting efficiency and bringing consistency to workflows, while improving success rates and reducing costs for patients.
According to Alex Christ, General Partner at Advance Venture Partners, the fertility industry stands at a critical inflection point where breakthrough innovation will fundamentally expand access to care.
Media Contact: press@conceivable.life
Source: Conceivable Life Sciences
